NeuroPace Inc (NASDAQ: NPCE) has raised its sales guidance for the fiscal year ending in 2026, signaling robust market reception for its medical devices. The company updated its full-year revenue outlook from a previous range of $99.000 million to $101.000 million to a new range of $99.500 million to $101.500 million. This adjustment places the midpoint of the guidance above the consensus estimate of $99.913 million, indicating that management anticipates revenue performance will exceed analyst expectations.

The revision reflects positive trends in the adoption of NeuroPace’s RNS System, a fully implantable vagus nerve stimulation device used for treating epilepsy. By raising the upper bound of its guidance by $0.500 million, the company highlights confidence in its commercial execution and recurring revenue streams from existing patients.

Guidance Update Details

The following table outlines the change in NeuroPace’s financial outlook:

The upward revision suggests that NeuroPace is successfully navigating the competitive landscape of neurostimulation therapies. The company’s ability to guide above estimates often correlates with increased hospital installations and higher patient activation rates, key drivers for long-term growth in the neuromodulation sector.

What the Numbers Show

The narrowness of the new guidance range ($2.000 million spread) compared to the previous range indicates reduced uncertainty in NeuroPace’s revenue forecasting. With the lower bound now at $99.500 million, the company has effectively set a floor that is closer to the consensus estimate, reducing downside risk for investors. This precision in guidance typically stems from improved visibility into order backlogs and service agreements, which constitute a significant portion of the company’s recurring revenue model.

NeuroPace, Inc. reported second quarter 2026 results that exceeded analyst expectations, with earnings per share of $(0.18) beating the consensus estimate of $(0.20) by 10 percent. The company’s total revenue reached $22.826 million, surpassing the $22.654 million forecast by 0.76 percent and marking a 17.05 percent increase from $19.501 million in the same period last year. This strong performance was driven by accelerated adoption of its RNS System, which generated $22.5 million in revenue, up 21.3% year-over-year.

The improved top-line growth contributed to a narrowing of losses compared to the prior year. While GAAP net loss stood at $6.2 million for the quarter ended June 30, 2026, it represented a significant improvement from the $10.0 million loss recorded in the second quarter of 2025. Non-GAAP metrics further reflected this operational efficiency, with adjusted EBITDA loss improving by $2.1 million to ($2.8) million, down from a loss of ($4.9) million in the previous year. Cash reserves remained robust at $51.9 million, providing ample liquidity despite long-term borrowings of $59.0 million.

Financial Performance

Revenue growth was primarily supported by increased adoption within the focal epilepsy indication. Non-GAAP gross margin declined slightly to 83.4% from 84.0% in the prior year, attributed to higher material costs that were partially offset by favorable pricing. GAAP gross margin from continuing operations remained robust at 82.8%. Operating expenses showed disciplined management, with non-GAAP general and administrative expense decreasing to $4.1 million from $4.6 million year-over-year due to the absence of one-time executive transition costs incurred previously.

Strategic Developments

NeuroPace launched ECoG Assistant™, its first AI-based clinical decision support tool, leveraging proprietary long-term intracranial EEG data to aid physicians in reviewing data and informing treatment decisions. The company also published 18-month NAUTILUS results in Epilepsia, demonstrating a 77% median reduction in generalized tonic-clonic seizures among patients with drug-resistant idiopathic generalized epilepsy. These clinical advancements support the company's ongoing engagement with the FDA regarding its IGE PMA Panel Track supplement.

What the Numbers Show

The divergence between GAAP and non-GAAP performance underscores the significant impact of non-cash charges on reported losses. While GAAP net loss was $6.2 million, non-GAAP net loss was only $3.9 million, indicating that stock-based compensation and other non-cash items constitute a substantial portion of the company's expenses. Furthermore, the rise in sales and marketing expense to $11.5 million from $10.7 million suggests aggressive scaling of commercial activities to drive the observed 21% growth in RNS revenue, a strategy that appears to be yielding immediate returns on investment.